CA2468839A1 - Methods of treating cancer using an fpt inhibitor and anti neoplastic agents - Google Patents

Methods of treating cancer using an fpt inhibitor and anti neoplastic agents Download PDF

Info

Publication number
CA2468839A1
CA2468839A1 CA002468839A CA2468839A CA2468839A1 CA 2468839 A1 CA2468839 A1 CA 2468839A1 CA 002468839 A CA002468839 A CA 002468839A CA 2468839 A CA2468839 A CA 2468839A CA 2468839 A1 CA2468839 A1 CA 2468839A1
Authority
CA
Canada
Prior art keywords
administered
amount
day
fpt inhibitor
twice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002468839A
Other languages
English (en)
French (fr)
Inventor
David L. Cutler
Michael L. Meyers
Charles Baum
Sara L. Zaknoen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2468839A1 publication Critical patent/CA2468839A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002468839A 2001-11-30 2002-11-25 Methods of treating cancer using an fpt inhibitor and anti neoplastic agents Abandoned CA2468839A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33441101P 2001-11-30 2001-11-30
US60/334,411 2001-11-30
PCT/US2002/037954 WO2003047697A2 (en) 2001-11-30 2002-11-25 Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer

Publications (1)

Publication Number Publication Date
CA2468839A1 true CA2468839A1 (en) 2003-06-12

Family

ID=23307076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002468839A Abandoned CA2468839A1 (en) 2001-11-30 2002-11-25 Methods of treating cancer using an fpt inhibitor and anti neoplastic agents

Country Status (13)

Country Link
US (2) US20030185831A1 (https=)
EP (1) EP1448268A2 (https=)
JP (1) JP2005511663A (https=)
CN (2) CN101181269A (https=)
AU (1) AU2002352941A1 (https=)
BR (1) BR0214564A (https=)
CA (1) CA2468839A1 (https=)
HU (1) HUP0402401A2 (https=)
MX (1) MXPA04005207A (https=)
NO (1) NO20042730L (https=)
NZ (1) NZ532562A (https=)
WO (1) WO2003047697A2 (https=)
ZA (1) ZA200403737B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312821A (pt) * 2002-07-24 2005-04-19 Akira Ohtsuru 4-(4-metil-piperazin-1-il-metil)-n-[(4-metil-3-(4-piridin-3-i l)-pirimidin-2-il-amino)-fenil]-benzamida para tratar câncer anaplásico da tireóide
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
JP2007510661A (ja) * 2003-11-06 2007-04-26 シェーリング　コーポレイション 乳癌の治療のための、ファルネシルトランスフェラーゼインヒビターと抗ホルモン剤との組合せ
EP1732583A4 (en) * 2004-02-26 2009-08-12 Penn State Res Found COMBINATORIES THERAPY FOR THE TREATMENT OF NEOPLASIA USING OPIOID GROWTH FACTOR RECEPTORS
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20080255171A1 (en) * 2005-10-07 2008-10-16 Manley Paul W Combination of Nilotinib with Farnesyl Transferase Inhibitors
US20100104661A1 (en) * 2006-10-25 2010-04-29 Susan Arbuck Discontinuous methods of treating cancer
EP2088862A4 (en) * 2006-11-28 2009-12-02 Smithkline Beecham Cork Ltd METHOD OF TREATING CANCER
KR20230098281A (ko) * 2020-10-27 2023-07-03 위스콘신 얼럼나이 리서어치 화운데이션 조합 면역요법을 위한 모듈형 덴드론 미셀
KR20250102088A (ko) 2022-11-09 2025-07-04 메르크 파텐트 게엠베하 선천성 항종양 면역을 유발시키기 위한 면역-자극제로서 Toll-유사 수용체 7 효현제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
PE20000042A1 (es) * 1997-12-22 2000-02-17 Schering Corp Uso combinado de un inhibidor de farnesilo transferasa y un agente antineoplasico y/o terapia de radiacion para el tratamiento de enfermedades proliferativas
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
SI1255537T1 (sl) * 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
ATE375794T1 (de) * 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
WO2001064252A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EP1265611A2 (en) * 2000-02-29 2002-12-18 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
CA2424797C (en) * 2000-10-05 2009-12-29 George Q. Daley Methods of inducing cancer cell death and tumor regression

Also Published As

Publication number Publication date
WO2003047697A2 (en) 2003-06-12
AU2002352941A1 (en) 2003-06-17
BR0214564A (pt) 2004-11-09
EP1448268A2 (en) 2004-08-25
WO2003047697A3 (en) 2003-10-30
US20030185831A1 (en) 2003-10-02
NO20042730L (no) 2004-06-29
CN101181269A (zh) 2008-05-21
MXPA04005207A (es) 2004-08-19
HUP0402401A2 (hu) 2005-03-29
US20060183765A1 (en) 2006-08-17
CN1617755A (zh) 2005-05-18
ZA200403737B (en) 2005-05-23
JP2005511663A (ja) 2005-04-28
NZ532562A (en) 2007-02-23

Similar Documents

Publication Publication Date Title
EP4506004A1 (en) Pharmaceutical composition, use thereof, and method for treating cancer
JP2021059564A (ja) 癌治療のための併用療法
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
TW200533339A (en) Therapeutic synergy of anti-cancer compounds
KR20090040926A (ko) 암 치료용 배합 생성물
JP2003533485A5 (https=)
JP2011522773A5 (https=)
KR20200096788A (ko) 화학치료법-내성 난소암 또는 유방암 치료에서 parp 억제제의 용도
CA2459822C (en) Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
JP2019508433A (ja) Ｌｉｖ１−ａｄｃ及び化学療法剤を用いた併用療法
US20060183765A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents
US20200352932A1 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
JP2005511663A5 (https=)
Cheng et al. Chronic oral etoposide and tamoxifen in the treatment of far‐advanced hepatocellular carcinoma
WO2004032925A1 (en) Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
Mayerhofer et al. Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy
MXPA06013902A (es) Procedimiento para tratar el crecimiento de celulas anormal.
AU2019311031A1 (en) IRE1α inhibitor in combination with cancer therapeutic agent for cancer treatment
AU2007201079A1 (en) Methods of treating cancer using an FPT inhibitor and antineoplastic agents
MX2007013830A (es) Terapia de combinacion.
JP2020528418A (ja) ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
KR20050116166A (ko) 이리노테칸의 저항성 유방암 치료용 용도
CN120154734A (zh) 维奈克拉联合瑞戈非尼在治疗急性髓系白血病中的应用
Von Pawel Topotecan (Hycamtin®): potent cytostatic action by selective topoisomerase I inhibition
Board et al. COI

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued